10-Q: Cardinal Health Q3 Fiscal 2026 Earnings Show Revenue Growth

Cardinal Health reported an 11% increase in revenue for the third quarter of fiscal year 2026, driven by strong performance in its Pharmaceutical and Specialty Solutions segment.

Summary

• Cardinal Health reported an 11% increase in revenue for the third quarter of fiscal year 2026, reaching $60.9 billion, and a 17% increase for the nine-month period to $190.6 billion.
• GAAP operating earnings decreased by 30% to $509 million for the quarter, impacted by a $184 million goodwill impairment charge and prior-year litigation recoveries.
• Non-GAAP operating earnings increased by 18% to $956 million for the quarter and by 30% to $2.7 billion for the nine-month period.
• GAAP diluted EPS decreased by 20% to $1.69 for the quarter, while Non-GAAP diluted EPS increased by 35% to $3.17.
• The acquisition of Solaris Health for approximately $1.9 billion was completed in November 2025, contributing to growth in the Pharma segment.
• The company paid $1.0 billion for share repurchases during the nine months ended March 31, 2026.
• Cash and equivalents remained stable at $3.9 billion as of March 31, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and significant increases in non-GAAP earnings and EPS, despite some GAAP headwinds from impairments and litigation.

Positives

• Revenue increased by 11% to $60.9 billion for the three months ended March 31, 2026, and by 17% to $190.6 billion for the nine months ended March 31, 2026.
• Non-GAAP operating earnings saw significant growth, increasing by 18% to $956 million for the quarter and 30% to $2.7 billion for the nine-month period.
• Non-GAAP diluted EPS increased by 35% to $3.17 for the quarter and 36% to $8.35 for the nine-month period.
• The Pharma segment revenue grew by 11% to $56.1 billion for the quarter and 18% to $176.0 billion for the nine months, driven by branded and specialty pharmaceutical sales.
• The Other segment revenue increased by 31% to $1.7 billion for the quarter and 34% to $5.1 billion for the nine months, due to growth in at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics.
• Gross margin increased by 18% to $2.5 billion for the quarter and 21% to $7.2 billion for the nine months.
• The acquisition of Solaris Health is expected to contribute to future growth.
• The company remains in compliance with its consolidated net leverage ratio covenant.

Negatives

• GAAP operating earnings decreased by 30% to $509 million for the three months ended March 31, 2026.
• GAAP diluted EPS decreased by 20% to $1.69 for the three months ended March 31, 2026.
• A $184 million pre-tax goodwill impairment charge was recognized for the Navista & ION reporting unit.
• GMPD segment profit decreased by 36% to $25 million for the three months ended March 31, 2026, primarily due to the adverse net impact of tariffs.
• Interest expense, net increased by 36% to $101 million for the quarter and 91% to $269 million for the nine months, due to additional debt financing for acquisitions.
• The company paid approximately $200 million in IEEPA tariffs as of Q3 FY26, with uncertainty remaining regarding the refund process.

Risks

• Tariffs imposed under the International Emergency Economic Powers Act (IEEPA) and other trade acts continue to impact financial results, with uncertainty surrounding the timing and scope of refunds.
• Future demand for GLP-1 pharmaceuticals is unpredictable and may be impacted by supply constraints.
• Executive orders and administrative policies related to prescription drug pricing may impact sales or profitability of branded pharmaceutical products.
• The company faces risks related to the integration and performance of its acquired Management Services Organization (MSO) platforms.
• Changes in foreign currency exchange rates could adversely affect financial results.
• Government import and export controls, including the Uyghur Forced Labor Prevention Act, could lead to supply disruptions and potential fines.
• Public health crises, extreme weather, geopolitical events, and other catastrophic events can disrupt operations and negatively impact financial results.
• Environmental and climate-related laws and regulations may impose additional costs.
• The company is involved in ongoing opioid litigation and investigations, with $4.3 billion accrued as of March 31, 2026.
• The IRS has asserted a potential additional federal income tax liability of approximately $160 million, plus interest, related to a past restructuring.

Future Outlook

The company believes it has adequate capital resources to fund operations and future cash needs. However, it may need to access capital markets for additional financing if it engages in one or more significant acquisitions. The company expects to return portions of any received IEEPA tariff refunds to customers. The ultimate resolution of tariff matters could positively impact future results.

Management Comments

• The performance of our MSO platforms positively impacted the year-over-year comparison of Pharma segment profit during the three and nine months ended March 31, 2026, primarily due to the impact of the acquisitions of GI Alliance ("GIA"), Urology America, and Solaris Health.
• The performance of our Pharma segment generics program positively impacted the year-over-year comparison of Pharma segment profit during the three and nine months ended March 31, 2026.
• We have taken actions to reduce the impact of IEEPA and other tariffs on our financial results, including through cost optimization initiatives and by increasing prices on impacted products to customers; however, these measures have not fully offset the negative impact.
• We currently believe that, based on available capital resources and projected operating cash flow, we have adequate capital resources to fund our operations and expected future cash needs.

Industry Context

StockSavvy.ai notes that Cardinal Health's Q3 FY2026 results reflect continued growth in its pharmaceutical distribution and services segment, bolstered by strategic acquisitions. The company's performance in medical products and distribution, however, is being impacted by macroeconomic factors like tariffs, highlighting the diverse challenges and opportunities within the healthcare supply chain industry.

Comparison to Industry Standards

• Cardinal Health's revenue growth of 11% for the quarter and 17% for the nine-month period outpaces the general healthcare distribution industry average, which typically sees single-digit growth.
• The significant increase in Non-GAAP operating earnings (18% quarterly, 30% year-to-date) suggests effective cost management and integration of recent acquisitions, potentially exceeding industry benchmarks for profitability improvement.
• The goodwill impairment charge of $184 million, while a negative, is not uncommon in the healthcare sector given the high valuations often associated with M&A activity, particularly in specialized areas like MSOs.
• The company's proactive approach to managing tariff impacts through cost optimization and price adjustments is a strategy employed by many global distributors facing similar trade policy uncertainties.

Legal Proceedings

• Ongoing opioid litigation and investigations, with $4.3 billion accrued as of March 31, 2026.
• Lawsuits related to insurance obligations for defense and indemnity costs in connection with opioid litigation.
• Department of Justice Civil Investigative Demand regarding potential violations of the Anti-Kickback Statute and False Claims Act.
• Product liability lawsuits involving claims of personal injuries associated with Inferior Vena Cava (IVC) filter products.
• Tax contingency related to a restructuring in connection with a 2017 acquisition, with the IRS asserting a potential additional tax liability of approximately $160 million plus interest.

Stakeholder Impact

• Shareholders: Positive impact from revenue growth and non-GAAP earnings increase, offset by GAAP earnings decline and goodwill impairment. Share repurchases may benefit shareholders.
• Employees: Impacted by restructuring and employee severance costs, but also by acquisition-related compensation costs.
• Customers: May see price increases on certain products due to tariffs, but also benefit from growth in branded and specialty pharmaceuticals. Potential for partial refund of IEEPA tariffs.
• Suppliers: Potential impact from tariffs on sourced materials and products.
• Creditors: Increased interest expense due to new debt financing for acquisitions.

Next Steps

• Continue to integrate acquired MSO platforms (Solaris Health, GIA, Urology America, ADS, ION).
• Monitor and manage the impact of tariffs and explore potential refunds.
• Address ongoing opioid litigation and investigations.
• Continue to evaluate and manage goodwill for impairment indicators.
• Manage interest expense through debt management and potential refinancing.
• Continue to execute share repurchase programs.

Key Dates

Recommendation

The company demonstrates strong operational execution with significant revenue and non-GAAP earnings growth, driven by strategic acquisitions. However, the GAAP earnings decline due to a substantial goodwill impairment, coupled with ongoing legal and regulatory challenges (opioid litigation, tariffs, tax disputes), introduces considerable uncertainty. While the core business appears healthy, these headwinds warrant a cautious 'hold' stance until the impact of these issues becomes clearer and their resolution is more certain.

Keywords

Cardinal Health, 10-Q, Q3 Fiscal 2026, Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution, Revenue Growth, Non-GAAP Earnings, Acquisitions, Solaris Health, Goodwill Impairment, Tariffs, Opioid Litigation